Brief: Genprex Receives Safety Review Committee Approval

Genprex

15/10/2024 14:30

Oct 15 (Reuters) - Genprex Inc  GNPX.O :
    * GENPREX RECEIVES SAFETY REVIEW COMMITTEE APPROVAL TO
ADVANCE TO
HIGHEST DOSE GROUP IN PHASE 1 PORTION OF ACCLAIM-3 CLINICAL
TRIAL OF REQORSA® GENE THERAPY IN COMBINATION WITH TECENTRIQ® IN
EXTENSIVE STAGE SMALL CELL LUNG CANCER

Source text for Eikon:  ID:nPn4Xbh4da 
Further company coverage:  GNPX.O 

 ((Reuters.Briefs@thomsonreuters.com;))